Ashish Nimgaonkar, MD
President and CEO of Glyscend Therapeutics, USA
Dr. Nimgaonkar is the president and CEO of Glyscend Therapeutics, a venture-backed biopharmaceutical company developing novel orally-delivered compounds that work on targets inside the GI tract to treat a variety of metabolic disorders, including T2D. He also serves as an assistant professor of medicine at Johns Hopkins University (JHU), a medical director at the Center for Bioengineering Innovation and Design in the JHU Biomedical Engineering department and an adjunct faculty at the JHU Carey Business School. Dr. Nimgaonkar leads numerous translational technology research projects at Johns Hopkins in the areas of gastrointestinal and metabolic diseases. His particular interest is to investigate the physiology behind various interventions to treat metabolic diseases such as diabetes and obesity and apply various engineering tools to develop novel therapies for these diseases.
Dr. Nimgaonkar has been an inventor of many technologies and a recipient of numerous awards including the AGA-Boston Scientific Career Development Technology & Innovation Award, and the CIMIT-Johnson & Johnson Young Clinician Award. His work has been supported by grants from both foundational and federal (NIH, NSF) agencies.